TY - JOUR ID - 161584 TI - Development of a Bilayer Mutual Tablet of Candesartan and Pioglitazone for Diabetic-Hypertensive Patients JO - Journal of Medicinal and Chemical Sciences JA - JMCS LA - en SN - AU - Hephzibah, Kola AU - Shanmugasundaram, Sangeetha AD - SRM College of Pharmacy, SRMIST, Kattankulathur, Chennai, Tamil Nadu-603203, India Y1 - 2023 PY - 2023 VL - 6 IS - 7 SP - 1517 EP - 1536 KW - Candesartan Cilexetil KW - Croscarmellose KW - mutual release dosage form KW - Design expert KW - Pioglitazone KW - Poloxamer 407 DO - 10.26655/JMCHEMSCI.2023.7.5 N2 - Background: Diabetes and hypertension are related illnesses that often coexist. Angiotensin receptor blockers like candesartan are typically used to treat Hypertension. A thiazolidinedione-type diabetes drug, pioglitazone helps those with type 2 diabetes manage their elevated blood sugar levels. The absence of a combination dose form on the market today may have industrial implications. Regulatory bodies advocate the use of a Quality by Design (QbD) methodology during the product development process to ensure product quality.Objective: The current study strives to develop an oral bilayer matrix tablet of candesartan Cilexetil and pioglitazone increasing patient compliance and decreasing the frequency of doses for treating hypertensive cardiovascular damage.Method: Poloxamer 407 was utilized as a polymer for immediate release. HPMC K4M and EUDRAGIT RS 100 for sustained release. Both layer blends were evaluated for precompression parameters. Using a 32-factorial design, the influence of the variables like disintegration time and time required for 100% drug release on Candesartan Cilexetil are measured.Results: The results show that HPMC forms a synergistic gel; controlling Pioglitazone medication release for 20 hours. Batch F6 with 40 mg Eudragit produces a film around drug, limiting its release rate to 24 hours. Candesartan Cilexetil immediate release layer demonstrated 100% drug release at 15 minutes.Conclusion: Quality by Design (QbD) approach offers an effective, efficient framework to incorporate Candesartan Cilexetil and Pioglitazone in a fixed dose bilayer tablet as this combo is beneficial for individuals who suffer from hypertension and type 2 diabetes. UR - https://www.jmchemsci.com/article_161584.html L1 - https://www.jmchemsci.com/article_161584_489abf601d7c9501839b8a2ca6199b7b.pdf ER -